Overstimulation of the NMDA receptors by glutamate is implicated in neurodegenerative disorders, including Alzheimer’s disease (AD) 1

The NMDA receptor antagonist memantine is approved for the treatment of moderate/severe AD alone or in combination with cholinesterase inhibitors2-4

Memantine has been shown to reduce clinical deterioration in moderate/severe AD1

Furthermore, treatment with memantine has been shown to reduce symptoms such as agitation, aggression, irritability,and appetite disturbances5

Acess our Slide Deck on treatment principles of AD and learn more about pharmacological treatment of AD.

file_download Download in HQ

Related content

description Article
Global perspectives on Alzheimer’s disease diagnosis and treatment: challenges and considerations in resource-limited settings

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease and the leading cause of dementia worldwide, regardless of socioeconomic status.

09.07.2024 Alzheimer’s Disease
grid_view Slide Deck
Alzheimer’s disease – History, definitions and diagnosis

Dementia is an umbrella term used to describe a state where an individual has lost the ability to carry out daily life activities independently because of cognitive impairment that is not due to an underlying psychiatric condition. Alzheimer’s disease (AD) refers to the abnormal presence of Aβ and tau proteins, which define AD among many other neurodegenerative diseases. Dementia -including dementia due to AD- is likely to be underestimated because of underdiagnosis and misdiagnosis.

15.12.2023 Alzheimer’s Disease
image Image 10 warning signs of dementia
10 warning signs of dementia

Usually, the first step for individuals with cognitive complaints in most countries is to visit their primary care physicians

15.12.2023 Alzheimer’s Disease